COVID-19 Drugmaker Leads 2 Latham-Led Cos.' $373M IPOs
Shares for a Latham-led biotechnology company that's developing a coronavirus treatment soared Friday as it and another Lathem-led life science business kicked off trading Friday for initial public offerings that raised...To view the full article, register now.
Already a subscriber? Click here to view full article